Our findings highlight the potential for both HIIT and MICT to help patients with CAD and co‐morbidities such as T2D to reduce their risk factor of adverse cardiac events by regulating the levels of certain inflammation‐related markers such as the cytokines discussed (i.e., FGF21, IL‐6, IL‐8, IL‐10, and IL‐18). This evidence concerns the gene FGF21 and type 2 diabetes mellitus.